retatrutide weight loss study results 🚨 Today, retatrutide, the GIP/GLP-1/glucagon triple agonist, just delivered TRIUMPH-2 top-line results. A in those with concurrent obesity and type 2 diabetes. 📊 Mean body change at 80 weeks: ⬇️ Eli Lilly infiltrates anti-obesity market

If your current provider is unfamiliar with or opposed to this approach, functional medicine practitioners and integrative rheumatologists are more likely to have experience with GLP-1 microdosing for autoimmune applications

FDA-approved options like Wegovy and Zepbound are regulated and reliable but cost $900$1,500+ per month without insurance

Significantly so

Excluding inadvertently enrolled individuals ( n = 6), the efficacy analysis set included 275 participants and their data prior to early treatment discontinuation or initiation of rescue therapy

The reason it matters in retatrutide research is the possibility that GIP activity may complement GLP-1 effects rather than duplicate them

What I find refreshing is I have never been pushed on buying anything